Pharmaceutical and biotechnology firmWockhardt today said it has received tentative approval from the US Food & Drug Administration (USFDA) to sell generic version of Sanofi Aventis' Allegra-D, used for treating allergic rhinitis.
In a statement the company said it has received tentative approval from the USFDA) for marketing the Fexofenadine HCl 60mg + Pseudoephedrine HCL 120mg extended release tablets which is used for treatment of seasonal allergic rhinitis without causing drowsiness.
Fexofenadine plus Pseudoephedrine is the generic name for the brand Allegra-D® 12 hour, marketed in the US by Sanofi Aventis.
"The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same," it said.
In a statement the company said it has received tentative approval from the USFDA) for marketing the Fexofenadine HCl 60mg + Pseudoephedrine HCL 120mg extended release tablets which is used for treatment of seasonal allergic rhinitis without causing drowsiness.
Fexofenadine plus Pseudoephedrine is the generic name for the brand Allegra-D® 12 hour, marketed in the US by Sanofi Aventis.
"The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same," it said.
No comments:
Post a Comment